Reichert Jessica, Gleicher Lily
Illinois Criminal Justice Information Authority, Center for Justice Research and Evaluation, 300 W. Adams St., Suite 200, Chicago, IL, 60606, USA.
Health Justice. 2019 May 28;7(1):10. doi: 10.1186/s40352-019-0089-6.
BACKGROUND: There is a gap between evidence-based treatment with medications for opioid use disorders (OUDs) and current practices of probation departments who supervise individuals with OUDs. Many probationers with OUDs cannot access FDA-approved medications to treat their disorders despite the strong evidence of their effectiveness. The barriers to medications for those under probation supervision include practitioners' negative attitudes toward medications, costs, stigma, and diversion risk. Probation officers have an ethical obligation to help their clients reduce barriers to access the care they need which in turn can improve their outcomes and increase public safety. RESULTS: The current study explores how probation departments respond to probationers with OUDs, focusing on the barriers to accessing OUD medications based on a survey of probation department directors/administrators (hereafter referred to as probation department leaders) in Illinois (N = 26). A majority of probation department leaders reported perceived staff barriers to their clients accessing medications. Reasons included lack of medical personnel experience, cost, need for guidance on medications, and regulations set by their organization or jurisdiction that prohibit client use of medications. Probation department leaders reported knowing less about the use of methadone and how it is administered, compared to buprenorphine and naltrexone. In addition, probation department leaders were generally more open to referring clients for treatment that include buprenorphine or naltrexone compared to methadone. Despite slightly less training or familiarity with methadone than the other medications, the number of probation department leaders who knew where to refer someone for each of the three FDA-approved medications was similar. CONCLUSIONS: The current study found probation department leaders perceive some barriers to their staff linking or referring their clients to OUD medications. Study findings indicate a need for administration- and staff-level training, interagency collaboration, and policy changes to increase access to, education on, and use of, medications for probation clients. Such efforts will ultimately help probation clients with OUDs stabilize and adhere to other probation requirements and engage in behavioral therapy, which may result in positive outcomes such as reduced recidivism, increased quality of life, and reduced mortality.
背景:阿片类物质使用障碍(OUD)的循证药物治疗与监督患有OUD的个体的缓刑部门当前的做法之间存在差距。尽管有充分证据证明其有效性,但许多患有OUD的缓刑人员无法获得美国食品药品监督管理局(FDA)批准的药物来治疗他们的疾病。缓刑监督下的人员获取药物的障碍包括从业者对药物的消极态度、成本、污名以及药物转移风险。缓刑官有道德义务帮助他们的客户减少获取所需护理的障碍,这反过来可以改善他们的结果并提高公共安全。 结果:本研究探讨了缓刑部门如何应对患有OUD的缓刑人员,重点关注基于对伊利诺伊州缓刑部门主管/管理人员(以下简称缓刑部门负责人)的调查(N = 26)获取OUD药物的障碍。大多数缓刑部门负责人报告称,他们认为工作人员在客户获取药物方面存在障碍。原因包括缺乏医务人员经验、成本、药物使用指导需求以及其组织或管辖区域制定的禁止客户使用药物的规定。与丁丙诺啡和纳曲酮相比,缓刑部门负责人报告称对美沙酮的使用及其给药方式了解较少。此外,与美沙酮相比,缓刑部门负责人通常更愿意将客户转介接受包括丁丙诺啡或纳曲酮的治疗。尽管与其他药物相比,对美沙酮的培训或熟悉程度略低,但知道将某人转介至三种FDA批准药物中每种药物治疗地点的缓刑部门负责人数量相似。 结论:本研究发现缓刑部门负责人认为其工作人员在将客户与OUD药物联系起来或转介客户使用OUD药物方面存在一些障碍。研究结果表明需要进行行政和工作人员层面的培训、跨机构合作以及政策变革,以增加缓刑客户获取、接受药物教育以及使用药物的机会。这些努力最终将帮助患有OUD的缓刑客户稳定下来并遵守其他缓刑要求,参与行为治疗,这可能会带来诸如降低再犯率、提高生活质量和降低死亡率等积极结果。
Health Justice. 2019-5-28
J Subst Abuse Treat. 2019-6-28
Intern Emerg Med. 2022-10
JAMA Psychiatry. 2021-7-1
Am J Drug Alcohol Abuse. 2020-11-1
Addict Sci Clin Pract. 2022-8-9
J Subst Use Addict Treat. 2024-12
J Subst Abuse Treat. 2022-6
JAMA. 2018-2-13
Health Aff (Millwood). 2017-12
J Subst Abuse Treat. 2017-7
Drug Alcohol Depend. 2016-10-1
N Engl J Med. 2016-3-31